copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Johnson Johnson’s dual-targeting CAR T-cell therapy shows encouraging . . . MILAN (June 13, 2025) – Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously
Johnson Johnson showcases latest advancements in cancer innovation . . . †See the NCCN Guidelines for detailed recommendations, including other treatment options ‡ The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories § The NCCN Content does not constitute medical advice
Contact us - Johnson Johnson Get in touch with Johnson Johnson You are now leaving jnj com The site you’re being redirected to is a branded pharmaceutical website
Johnson Johnson: Changing health for humanity Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases
Johnson Johnson Reports Q4 and Full-Year 2024 Results NEW BRUNSWICK, N J --(BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024 "2024 was a transformative year for Johnson Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson
Products - Johnson Johnson Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases